| Name | Title | Contact Details |
|---|
Bioderm Sciences is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Procyrion is developing the first catheter-deployed circulatory assist device intended for long-term use. The Procyrion device will be the first minimally invasive tool for cardiologists to treat over 1M NYHA Class III and early class IV heart failure (HF) patients in the US who have few therapeutic options. In partnership with Texas Heart Institute, Procyrion is currently conducting preclinical testing of the Procyrion device.
Avalign Technologies is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
NovaMed Corporation is a Trumbull, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Contego Medical, founded in 2005, has developed a family of novel emboli protection devices. The main feature of each device is that the treatment portion (i.e., balloon or stent) is on the same catheter as the embolic protection device, thus coupling the two together. This device can act as an angioplasty balloon with an integrated emboli protection device. If a stent is mounted on the balloon, it can serve as a stent with an integrated emboli protection device. We know that embolization occurs with all angioplasty and stenting procedures. It is usually hard to predict which ones will result in clinical sequalae. Despite knowing that embolization is ubiquitous, embolic protection devices are not used in all procedures as they add complexity, time, and cost. Dedicated devices do not exist for renal intervention, although the majority of physicians say they would use one if it existed. Contego Medical’s family of embolic protection devices represent a paradigm shift in the treatment of cardiovascular disease.